PCOS involves genetic and immune factors, especially T cells, affecting its development.
January 2025 in “Clinical Cosmetic and Investigational Dermatology” Pediatric alopecia areata is more immune-active than adult cases, suggesting age-specific treatments and potential use of JAK inhibitors.
July 2024 in “Journal of Investigative Dermatology” CD8+ T cells attack hair follicle stem cells, causing scarring and hair loss in Discoid Lupus.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
December 2021 in “OPAL (Open@LaTrobe) (La Trobe University)” New therapies like JAK inhibitors and stem cells show promise in treating vitiligo.
178 citations
,
June 1994 in “Journal of Investigative Dermatology” Alopecia areata in these mice is inherited, more common in young females, and can be treated with triamcinolone acetonide.
November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” The study suggests that a specific type of immune cell, memory-like NK cells, may increase during active hair loss in Alopecia areata.
2 citations
,
July 2014 in “Our Dermatology Online” Contact immunotherapy can cause vitiligo in patients with autoimmune conditions.
1 citations
,
January 2017 in “Springer eBooks” Understanding the immune-related causes of Alopecia Areata has led to potential treatments like JAK inhibitors.
20 citations
,
November 2005 in “Journal of Investigative Dermatology Symposium Proceedings” IFN-γ and IL-2 are important for T cell activation in hair loss in mice.
September 2021 in “CRC Press eBooks” Lichen planopilaris causes permanent hair loss and scarring due to damage to hair follicles and can be mistaken for other hair loss conditions.
5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
April 2019 in “Journal of Investigative Dermatology” Gut microbiota influences the development of alopecia areata.
March 2014 in “The Journal of Urology” Finasteride increases CD8+ T cells in BPH tissues.
June 2025 in “bioRxiv (Cold Spring Harbor Laboratory)” In alopecia areata, certain immune cells increase and express a protein linked to immune activation.
November 2025 in “The Journal of Immunology” BST2 is highly expressed in certain immune cells in alopecia areata, suggesting a role in the disease.
12 citations
,
September 2022 in “Frontiers in Genetics” Enhancing CD8+ T cell function to induce ferroptosis in tumor cells may help treat skin melanoma.
May 2025 in “Nonlinear Analysis Real World Applications” Reducing CD8+ T cell growth can stabilize alopecia areata.
1 citations
,
July 2025 in “Journal of Investigative Dermatology” IL-27 may help prevent hair loss by creating immune-suppressing cells.
January 2026 in “Experimental Dermatology” Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.
February 2025 in “International Journal of Molecular Sciences” RIPK1 inhibitors may help prevent alopecia areata by reducing immune cell activity.
February 2024 in “Skin research and technology” The research suggests that immune cells and a specific type of cell death called ferroptosis are involved in Frontal fibrosis alopecia.
3 citations
,
July 2023 in “International journal of molecular sciences” Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.
2 citations
,
November 2015 in “Journal of Investigative Dermatology” RANKL improves the immune response against herpes simplex virus by enhancing T cell activation and could help develop better treatments or vaccines.
55 citations
,
October 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.
November 2025 in “The Journal of Immunology” The S1PR 1&4 modulator may effectively treat alopecia areata by reducing hair loss and immune cell activity.
September 2019 in “Journal of Investigative Dermatology” IL-17 and certain immune cells are linked to more severe alopecia areata.
1 citations
,
January 2014 in “The Journal of Dermatology” A patient with Ivemark syndrome developed mixed type vitiligo after a hepatitis C infection, showing different treatment responses and immune cell involvement in the skin.